1. Protein Tyrosine Kinase/RTK Immunology/Inflammation Apoptosis
  2. Btk Pyroptosis
  3. BTK-IN-15

BTK-IN-15 (compound 42) 是一种新型的布鲁顿酪氨酸激酶 (BTK) 抑制剂,具有良好口服活性。BTK-IN-15 抑制 BTKIC50 为 0.7 nM,并具有良好的激酶选择性和抗肿瘤活性,能诱导癌细胞凋亡 (apoptosis)。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

BTK-IN-15 Chemical Structure

BTK-IN-15 Chemical Structure

CAS No. : 2820426-92-2

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

BTK-IN-15 (compound 42) is a potent Bruton's tyrosine kinase (BTK) inhibitor with high oral absorption. BTK-IN-15 inhibits BTK with an IC50 value of 0.7 nM. BTK-IN-15 displays excellent kinase selectivity, antitumor activity, and induces apoptosis[1].

IC50 & Target

IC50: 0.7 nM (BTK)[1]

体外研究
(In Vitro)

BTK inhibition is an effective approach against B-cell malignancies[1].
BTK-IN-15 (compound 42) demonstrates inhibitory against TMD8 with an IC50 value of 2.6 nM[1].
BTK-IN-15 (1 μM; 1 h) displays significant selectivity to BTK over EGFR kinase with 0.05% and 44% of the control, respectively[1].
BTK-IN-15 (0-1 mM; 72 h) exerts potent anti-proliferative activity against a human mantle cell lymphoma cell line (REC-1) with an IC50 value of 1.7 nM[1].
BTK-IN-15 (0-1 mM; 2 h) inhibits BTK auto-phosphorylation with an IC50 value of 1.49 nM[1].
BTK-IN-15 (0-100 nM; 48 h) arrests cell cycle at G1 phase and (0-1 mM; 72 h) induces apoptosis in TMD8[1].
BTK-IN-15 shows low hERG channel activity (IC50=4.38 μM), indicating low cardiotoxicity[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: B-cell lymphoma (DLBCL) TMD8 cancer cells
Concentration: 0, 0.15, 0.46, 1.37, 4.12, 12.35, 37.04, 111, 333, 1000 nM
Incubation Time: 2 hours
Result: Inhibited BTK auto-phosphorylation at the Tyr223 site with an IC50 value of 1.49 nM.

Cell Cycle Analysis[1]

Cell Line: B-cell lymphoma (DLBCL) TMD8 cancer cells
Concentration: 0, 10, 100 nM
Incubation Time: 48 hours
Result: Arrested cell cycle progression at G1 phase in a dose-dependent manner, the percentage of cells in the G0/G1 phase increased from 33.0 to 63.0% with a dose range of 1-100 nM.

Apoptosis Analysis[1]

Cell Line: B-cell lymphoma (DLBCL) TMD8 cancer cells
Concentration: 0, 10, 100, 1000 nM
Incubation Time: 72 hours
Result: Induced apoptosis of TMD8 cells in a weakly triggered concentration-dependent manner, with the apoptosis cell values of 19% (10 nM), 25.2% (100 nM), and 31.4% (1000 nM), respectively.
体内研究
(In Vivo)

BTK-IN-15 (compound 42) (12.5-50 mg/kg; p.o.; twice daily; 21 d) inhibits tumor growth (TGI = 104%) at a dosage of 50 mg/kg in mice[1].
BTK-IN-15 (300, 400, 500 mg/kg; p.o.; twice daily; 14 d) has biological safety and displays no affect against body weight in mice compared with control[1].
BTK-IN-15 (10 mg/kg; p.o.) shows a high oral bioavailability of 40.98% in mice[1].
Pharmacokinetics of BTK-IN-15 in Mice[1]

Route Dose (mg/kg) Tmax (h) Cmax (ng/mL) AUC(0-t) (h•ng/mL) AUC(0-∞) (h•ng/mL) T1/2 (h) Vz (L/kg) CL (L/h/kg) F (%)
i.v. 2 0.03 2245.39 1471.35 718.33 0.67 2.79 2.87 40.98
p.o. 10 0.39 1441.59 718.33 1472.06 0.59

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female CB-17 SCID nude mice with TMD8 xenograft model[1]
Dosage: 12.5 mg/kg, 25 mg/kg, and 50 mg/kg
Administration: Oral gavage; twice daily; 21 days
Result: Inhibited tumor growth at a dosage of 50 mg/kg and reduced tumor volume after 21 days with a TGI of 104%.
Reduced the content of white blood cells, lymphocytes and monocytes, while showed no effect on red blood cell and platelets.
Animal Model: ICR mice (acclimation for 5 days, 18-20 g)[1]
Dosage: 300, 400, 500 mg/kg
Administration: Oral gavage; 14 days
Result: Demonstrated no affect against body weight in mice compared with control.
分子量

481.52

Formula

C28H24FN5O2

CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
BTK-IN-15
目录号:
HY-150752
需求量: